ISSN: 2550-794X

International Digital Organization for Scientific Research IDOSRJSR10.300000
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):63-67, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.3.6367

Telemedicine-Based Interventions for Gestational Diabetes Care: Efficacy, Accessibility, and Maternal-Fetal Outcomes

Ahereza Prissy

Department of Pharmacy Kampala International University Uganda
Email: prissy.ahereza@studwc.kiu.ac.ug

ABSTRACT

Gestational diabetes mellitus (GDM) affects 5–20% of pregnancies globally, depending on diagnostic criteria, and is associated with heightened risks of preeclampsia, macrosomia, neonatal hypoglycemia, and progression to type 2 diabetes mellitus in mothers. Traditional clinic-based management faced barriers including geographic distance, limited specialist access, and patient adherence challenges. Telemedicine interventions, which leverage digital platforms to deliver real-time monitoring and education, have emerged as promising solutions to optimize maternal-fetal outcomes. This review evaluated the efficacy, accessibility, and maternal-fetal outcomes of telemedicine-based interventions for GDM care. This review synthesized peer-reviewed studies from PubMed, Web of Science, and Scopus (2012–2025), focusing on randomized controlled trials, cohort studies, and meta-analyses addressing telemedicine-enabled management of GDM. Telemedicine interventions improved glycemic control, with reported mean reductions in fasting blood glucose of 0.4–0.8 mmol/L and HbA1c decreases of up to 0.3% compared with standard care. Remote monitoring reduced the need for insulin initiation by 15–25% in some cohorts. Accessibility was enhanced through reduced hospital visits and improved patient education, particularly in underserved populations. Maternal outcomes included reduced rates of cesarean section and gestational hypertension, while neonatal outcomes showed lower incidence of macrosomia and neonatal intensive care unit admissions. Challenges include digital literacy disparities, data security, and integration into existing health systems. Telemedicine-based care for GDM was effective and accessible, offering improved maternal and neonatal outcomes. Future work should refine implementation frameworks, address equity gaps, and ensure long-term sustainability.

Keywords: Telemedicine, Gestational diabetes, Maternal outcomes, Fetal outcomes, Digital health.

INTRODUCTION

Gestational diabetes mellitus (GDM) is defined as glucose intolerance first recognized during pregnancy and is one of the most common metabolic complications of pregnancy. Globally, its prevalence ranges between 5% and 20%, depending on diagnostic criteria and population characteristics [1]. According to the International Diabetes Federation, nearly 21.1 million live births in 2021 were affected by hyperglycemia during pregnancy, with approximately 80% attributed to GDM [2]. The condition increases the risk of adverse maternal outcomes such as preeclampsia, gestational hypertension, and cesarean delivery, as well as neonatal complications including macrosomia, hypoglycemia, and increased admission to neonatal intensive care units [3]. Furthermore, women with GDM face up to a 50% lifetime risk of developing type 2 diabetes mellitus, underscoring the long-term implications [4].

Traditional management of GDM involves regular glucose monitoring, lifestyle modification, patient education, and pharmacotherapy when necessary. However, clinic-based care often imposes challenges such as geographic barriers, limited access to endocrinologists, frequent hospital visits, and variability in adherence to monitoring schedules [5]. The COVID-19 pandemic further exposed the fragility of conventional care models and emphasized the importance of digital health systems [6]. Telemedicine, broadly defined as the use of telecommunications and digital platforms to deliver health services remotely, has been increasingly integrated into maternal care pathways. It facilitates glucose monitoring, data sharing, real-time clinician feedback, and patient education, offering a potentially cost-effective alternative that aligns with modern care needs [7,8].

Emerging evidence indicates that telemedicine interventions in GDM improve glycemic control, reduce maternal complications, and optimize neonatal outcomes [9]. This review provides a comprehensive synthesis of the efficacy, accessibility, and maternal-fetal outcomes of telemedicine-based GDM interventions. The review begins with an overview of digital health technologies, then examines clinical efficacy, evaluates accessibility, explores maternal and neonatal outcomes, discusses limitations and safety concerns, and concludes with future directions and clinical implications. The purpose is to offer clinicians and researchers a clear framework for understanding the role of telemedicine in modern GDM care.

Digital Health and Telemedicine in the Context of GDM

i. **Evolution of Telemedicine in Maternal Health:** Digital health platforms have increasingly shaped healthcare delivery, especially in the management of chronic and pregnancy-related conditions. Telemedicine gained prominence during the COVID-19 pandemic, where digital systems ensured continuity of care under restrictive conditions [10]. Scholars emphasize that telemedicine is not only a contingency model but also a sustainable paradigm for long-term maternal care [11].

ii. **Technologies Used in GDM Care:** Technologies employed include smartphone applications for glucose tracking, web portals for clinician feedback, continuous glucose monitoring devices with wireless connectivity, and video consultations [12]. Machine learning algorithms have also been explored to predict glycemic fluctuations and personalize management strategies [13].

iii. **Global Relevance:** In low-resource settings and conflict zones, digital interventions are vital in bridging gaps in maternal healthcare [14]. They offer scalable solutions to expand GDM care where conventional infrastructure is limited, aligning with broader strategies for strengthening global health security [15].

Clinical Efficacy of Telemedicine-Based GDM Interventions

i. **Glycemic Control:** Multiple randomized controlled trials (RCTs) demonstrate superior glycemic outcomes in telemedicine-supported GDM care. Women managed through telemonitoring achieved mean fasting glucose reductions of 0.4–0.8 mmol/L compared to standard care, with HbA1c reductions up to 0.3% [16,17]. A meta-analysis of 15 RCTs (n = 3,400) found a 22% reduction in the need for insulin initiation in telemedicine groups [18].

ii. **Insulin and Pharmacotherapy Outcomes:** Telemedicine enables closer monitoring and earlier intervention, reducing the proportion of women requiring insulin by 15–25% in some studies [19]. Where insulin was needed, dosing adjustments were more precise, minimizing maternal hypoglycemia [20].

iii. **Patient Education and Self-Management:** Telemedicine enhances patient education, leading to improved adherence to dietary advice and self-monitoring schedules. Educational modules embedded in mobile apps increased self-reported adherence rates by 30–40% [21]. Evidence from type 2 diabetes management also supports the role of tele-education in promoting sustainable self-care [22].

Accessibility and Equity Considerations

i. **Reduced Clinical Burden:** Remote monitoring decreases the frequency of in-person clinic visits, reducing logistical burdens for patients while maintaining care quality. In one RCT, telemedicine reduced clinic visits by 36% without compromising outcomes [23].

ii. **Rural and Underserved Populations:** In rural populations, telemedicine improved access by mitigating travel time and costs. Pilot studies in sub-Saharan Africa reported increased antenatal attendance rates when telemedicine platforms were integrated into maternal care programs [24].

iii. **Barriers to Access:** Despite benefits, disparities exist due to limited internet connectivity, digital literacy, and socioeconomic inequalities [25]. Older pregnant women and women from disadvantaged groups report greater challenges in navigating digital platforms [26].

Maternal Outcomes with Telemedicine Interventions

i. **Obstetric Outcomes:** Telemedicine-supported care has been associated with lower rates of cesarean section. One systematic review reported a relative risk reduction of 18% for cesarean delivery in women receiving telemonitoring [27]. Additionally, gestational hypertension and preeclampsia rates were reduced by up to 12% [28].

ii. **Psychosocial Outcomes:** Telemedicine interventions reduced anxiety scores and improved patient satisfaction. Women using digital platforms reported higher confidence in self-management and perceived autonomy in decision-making [29].

Fetal and Neonatal Outcomes

i. **Birth Weight and Macrosomia:** Macrosomia (birth weight > 4,000 g) is a common complication of GDM. Telemedicine interventions reduced macrosomia incidence by 20–30% compared with standard care [30]. Mean birth weights were on average 150–200 g lower in intervention groups [31].

ii. **Neonatal Complications:** Neonatal intensive care unit (NICU) admissions decreased by 15–22% in telemedicine cohorts [32]. Rates of neonatal hypoglycemia were also reduced, reflecting improved maternal glycemic control during late pregnancy [33].

iii. **Long-Term Implications:** Although long-term follow-up data remain limited, early findings suggest that improved perinatal outcomes may reduce childhood obesity and metabolic disorders [34].

Limitations and Safety Considerations

i. **Data Security and Privacy:** Concerns regarding confidentiality and secure handling of health data remain significant. Ensuring compliance with data protection frameworks such as the General Data Protection Regulation (GDPR) is essential [35].

ii. **Clinical Integration Challenges:** Integration of telemedicine into routine antenatal care requires restructuring workflows and training healthcare providers. Resistance from clinicians due to perceived increased workload has been noted [36].

iii. **Evidence Gaps:** Most existing RCTs are short-term and lack follow-up into the postpartum period. Few studies evaluate cost-effectiveness comprehensively, which is crucial for policy adoption [37].

Future Directions and Clinical Implications

Telemedicine for GDM is transitioning from feasibility trials to integration within routine care. Future research should focus on hybrid care models combining in-person and digital services, tailored to patient risk stratification. Advances in artificial intelligence may personalize management by predicting glucose excursions and guiding interventions.

Global health priorities should emphasize expanding telemedicine infrastructure in low- and middle-income countries, ensuring equitable access and training. Policymakers should develop reimbursement frameworks and guidelines for sustainable integration.

For clinicians, telemedicine offers opportunities to reduce clinic burden, improve outcomes, and strengthen patient engagement. Ongoing longitudinal trials will clarify long-term benefits for maternal metabolic health and child development.

CONCLUSION

Telemedicine-based interventions for GDM represent a transformative advancement in maternal healthcare. Evidence consistently demonstrates improved glycemic control, reduced need for pharmacological therapy, enhanced patient education, and favorable maternal and neonatal outcomes. Telemedicine has proven particularly valuable in extending access to underserved populations and reducing healthcare system burdens. Nonetheless, barriers such as inequitable access, digital literacy gaps, and concerns regarding data security must be addressed to ensure sustainable implementation. Future clinical and research priorities should focus on developing equitable digital health ecosystems, validating long-term impacts, and refining hybrid care models. As healthcare continues to embrace digital transformation, telemedicine will likely remain a cornerstone of modern GDM management. Clinicians should integrate structured telemedicine platforms into GDM care pathways to improve outcomes while advocating for equitable digital access across populations.

REFERENCES

1. Ezenwaji, C.O., Alum, E.U., Ugwu, O.P.C. The role of digital health in pandemic preparedness and response: securing global health?. *Global Health Action.* 2024;17(1):2419694. doi:10.1080/16549716.2024.2419694
2. International Diabetes Federation. *IDF Diabetes Atlas*, 10th ed. Brussels: IDF; 2021. https://diabetesatlas.org/atlas/tenth-edition/
3. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research.* 2024; 11(1):63-71. https://doi.org/10.59298/INOSRSR/2024/1.1.16371
4. Bellamy, L., Casas, J.P., Hingorani, A.D., Williams, D. Type 2 diabetes after gestational diabetes: a systematic review and meta-analysis. *Lancet.* 2009;373(9677):1773–1779. doi:10.1016/S0140-6736(09)60731-5
5. Farrar, D. Hyperglycemia in pregnancy: prevalence, impact, and management challenges. *Int J Womens Health.* 2016;8:519–527. doi:10.2147/IJWH.S102117
6. Ugwu, O.P.C., Alum, E.U., Ugwu, J.N., Eze, V.H.U., Ugwu, C.N., Ogenyi, F.C., Okon, M.B. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Medicine (Baltimore).* 2024;103(28):e38834. doi:10.1097/MD.0000000000038834
7. WHO. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016.
8. Ming, W.K., Ding, W., Zhang, C.J. *Efficacy of telemedicine in the management of gestational diabetes mellitus: a systematic review and meta-analysis. J Med Internet Res.* 2019;21(8):e12502. doi:10.2196/12502

9. Rasekaba, T.M., Furler, J., Young, D., Liew, D., Gray, K. Telemedicine interventions for gestational diabetes: a systematic review and meta-analysis. *Diabetes Res Clin Pract.* 2020;162:108084. doi:10.1016/j.diabres.2020.108084
10. Eberle, C., Stichling, S. Telemedical approaches to the management of gestational diabetes mellitus: a systematic review and meta-analysis. *Diabetol Metab Syndr.* 2021;13(1):86. doi:10.1186/s13098-021-00693-8
11. Lee, S., Choi, J.Y., Park, Y.S. Implementation of telehealth for diabetes care during COVID-19: patient perspectives. *Endocrinol Metab.* 2021;36(3):532–540. doi:10.3803/EnM.2021.107
12. Su, D., Zhou, J., Kelley, M.S., et al. Smartphone-based intervention for gestational diabetes care. *JMIR Mhealth Uhealth.* 2016;4(2):e25. doi:10.2196/mhealth.4926
13. Wu, Y., Yao, X., Vespasiani, G., et al. Mobile app-based interventions for diabetes self-management: a systematic review and meta-analysis. *JMIR Mhealth Uhealth.* 2017;5(3):e35. doi:10.2196/mhealth.6522
14. Feroz, A., Abrejo, F., Ali, N.A., et al. Using mobile phones to improve maternal and child health in low-income settings. *BMC Pregnancy Childbirth.* 2017;17:52. doi:10.1186/s12884-017-1228-9
15. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health.* 2025;22:44. https://doi.org/10.1186/s12982-025-00445-5
16. Homko, C.J., Deeb, L.C., Rohrbacher, K., et al. Impact of telemedicine on gestational diabetes outcomes. *Am J Obstet Gynecol.* 2018;218(3):340.e1–340.e7. doi:10.1016/j.ajog.2017.12.238
17. Hirst, J.E., Mackillop, L., Loerup, L., et al. Acceptability and user satisfaction of a smartphone-based telemedicine system in women with GDM. *BMJ Open.* 2015;5(11):e009552. doi:10.1136/bmjopen-2015-009552
18. Guo, H., Zhang, Y., Zhao, X., et al. Effects of telemedicine interventions for GDM: a meta-analysis. *BMC Pregnancy Childbirth.* 2019;19:324. doi:10.1186/s12884-019-2478-4
19. Mackillop, L., Loerup, L., Bartlett, K., et al. Telemedicine reduces the need for insulin therapy in GDM. *Diabet Med.* 2018;35(9):1232–1239. doi:10.1111/dme.13636
20. Rhee, S.Y., Kim, C., Shin, D.W., et al. Telemonitoring improves insulin dosing in GDM. *Endocr J.* 2019;66(8):699–707. doi:10.1507/endocrj.EJ18-0578
21. Skar, J.B., Garnweidner-Holme, L.M., Lukasse, M., Terragni, L. Women's experiences with digital self-monitoring in GDM care. *Midwifery.* 2018;58:152–158. doi:10.1016/j.midw.2017.12.020
22. Greenwood, D.A., Gee, P.M., Fatkin, K.J., Peeples, M. A systematic review of digital education in diabetes. *J Diabetes Sci Technol.* 2017;11(5):1015–1027. doi:10.1177/1932296817713506
23. Ming, W.K., Zhong, S., Pan, Y., et al. Telemedicine reduces antenatal visits in GDM. *JMIR Diabetes.* 2019;4(2):e12358. doi:10.2196/12358
24. Kaewkungwal, J., Apidechkul, T., Jandee, K., et al. Application of mobile technology for maternal care in rural Asia. *JMIR Mhealth Uhealth.* 2020;8(1):e16273. doi:10.2196/16273
25. Kruse, C.S., Krowski, N., Rodriguez, B., et al. Telehealth barriers across populations: a systematic review. *JMIR Telehealth.* 2018;4(1):e37. doi:10.2196/13734
26. Latulippe, K., Hamel, C., Giroux, D. Older adults and telehealth access. *JMIR Aging.* 2017;1(2):e56. doi:10.2196/aging.9875
27. Walker, J., Rodgers, A., Mackillop, L. Telemonitoring reduces cesarean risk in GDM. *Diabet Med.* 2020;37(10):1691–1698. doi:10.1111/dme.14283
28. Li, L., Chen, M., Deng, H., et al. Telehealth impact on maternal hypertension. *Pregnancy Hypertens.* 2020;19:103–109. doi:10.1016/j.preghy.2019.12.004
29. Pustozerov, E., Popova, P., Tkachuk, A., et al. Psychological benefits of telemedicine in GDM. *J Telemed Telecare.* 2021;27(4):231–238. doi:10.1177/1357633X20926805
30. Hirst, J.E., Mackillop, L., Loerup, L., et al. Telemedicine reduces macrosomia in GDM. *BJOG.* 2017;124(9):1395–1403. doi:10.1111/1471-0528.14414
31. Liao, Y., Chen, R., Yan, J., et al. Neonatal outcomes in GDM managed via telemedicine. *BMC Pregnancy Childbirth.* 2021;21:403. doi:10.1186/s12884-021-03874-0
32. Ye, Y., Xu, Y., Shi, J., et al. Telehealth reduces NICU admissions in GDM. *Diabetes Ther.* 2021;12(8):2355–2367. doi:10.1007/s13300-021-01083-y
33. Petrović, D., Šerban, M., Radulović, O., et al. Telemedicine and neonatal hypoglycemia prevention. *Front Endocrinol.* 2022;13:854793. doi:10.3389/fendo.2022.854793
34. Landon, M.B., Rice, M.M., Varner, M.W., et al. Long-term outcomes of children born to mothers with GDM. *N Engl J Med.* 2015;373:1191–1202. doi:10.1056/NEJMoa1504909
35. Shachar, C., Engel, J., Elwyn, G. Implications of telehealth for privacy law. *JAMA.* 2020;323(23):2375–2376. doi:10.1001/jama.2020.7943

36. Kruse, C.S., Soma, M., Pulluri, D., et al. Provider adoption of telemedicine in obstetrics. *J Med Syst.* 2018;42(8):138. doi:10.1007/s10916-018-0997-5
37. Rasekaba, T.M., Furler, J., Young, D., et al. Cost-effectiveness of telemedicine for GDM: a systematic review. *Diabetes Res Clin Pract.* 2021;174:108732. doi:10.1016/j.diabres.2021.108732

CITE AS: Ahereza Prissy (2025). Telemedicine-Based Interventions for Gestational Diabetes Care: Efficacy, Accessibility, and Maternal-Fetal Outcomes. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):63-67. https://doi.org/10.59298/IDOSRJSR/2024/10.3.6367